Since 7 out of 14 patients in the schizophrenia group were diagnosed with schizoaffective disorder, we carried out a separate higher level analysis to examine DMN differences between patients with schizophrenia and schizoaffective disorder. This analysis is underpowered and its results should be interpreted with caution. In addition, since all patients in the study were taking medication at scan time, we repeated the higher-level analysis for bipolar disorder and schizophrenia groups with de-meaned chlorpromazine (CPZ) equivalents as covariate to examine any antipsychotic medication effect on ICA results. We conducted a similar analysis with the schizophrenia group with de-meaned PANSS scores as covariate, and a third analysis with the bipolar disorder group with de-meaned YMRS scores as covariate.
